GSK scores major trial win with potential multiple myeloma blockbusterGlaxoSmithKline may have scored a major cancer trial win after its belantamab mafodotin hit targets in the pivotal Share XGSK scores major trial win with potential multiple myeloma blockbusterhttps://pharmaphorum.com/news/gsk-scores-major-trial-win-with-potential-multiple-myeloma-blockbuster/
GSK hires former Genentech expert for AI unitGlaxoSmithKline has hired computational drug design specialist Dr Kim Branson to expand its artificial intelligence and machine learning Share XGSK hires former Genentech expert for AI unithttps://pharmaphorum.com/news/gsk-hires-former-genentech-expert-for-ai-unit/
FDA reviews Sanofi’s multiple myeloma drug isatuximabThe FDA has begun its review of Sanofi’s multiple myeloma drug isatuximab, as the French pharma prepares for Share XFDA reviews Sanofi’s multiple myeloma drug isatuximabhttps://pharmaphorum.com/news/fda-reviews-sanofis-multiple-myeloma-drug-isatuximab/
FDA clears Karyopharm’s myeloma drug despite advisory panel rejectionThe FDA has taken the unusual step of over-ruling its own advisory committee and approving Karyopharm’s Xpovio as Share XFDA clears Karyopharm’s myeloma drug despite advisory panel rejectionhttps://pharmaphorum.com/news/fda-clears-karyopharms-myeloma-drug-despite-advisory-panel-rejection/
Janssen to develop Darzalex successor with GenmabJanssen has signed a licence and option deal with Denmark’s Genmab to develop a next-generation drug that it Share XJanssen to develop Darzalex successor with Genmabhttps://pharmaphorum.com/news/janssen-to-develop-darzalex-successor-with-genmab/
EU regulators to fast-track Janssen’s multiple myeloma CAR-TEuropean regulators are to hasten development of Janssen’s CAR-T therapy for patients with multiple myeloma, after promising early-stage Share XEU regulators to fast-track Janssen’s multiple myeloma CAR-Thttps://pharmaphorum.com/news/eu-regulators-to-fast-track-janssens-multiple-myeloma-car-t/
GSK mulls filings for multiple myeloma drugGlaxoSmithKline has announced more data making the case for its multiple myeloma antibody-drug conjugate GSK2857916, confirming that almost Share XGSK mulls filings for multiple myeloma drughttps://pharmaphorum.com/news/gsk-mulls-filings-for-multiple-myeloma-drug/
Question marks over AbbVie/Roche’s venetoclax after safety scareAbbVie and Roche have stopped recruiting patients for all multiple myeloma trials involving the drug venetoclax after a Share XQuestion marks over AbbVie/Roche’s venetoclax after safety scarehttps://pharmaphorum.com/news/question-marks-over-abbvie-roches-venetoclax-after-aml-safety-scare/
NICE backs interim funding for J&J/Takeda myeloma regimenA three-drug regimen for multiple myeloma based on Johnson & Johnson’s Darzalex, Takeda’s Velcade and dexamethasone will be Share XNICE backs interim funding for J&J/Takeda myeloma regimenhttps://pharmaphorum.com/news/nice-backs-interim-funding-for-jj-takeda-myeloma-regimen/
